Effect of Waon Therapy on Oxidative Stress in Chronic Heart Failure

Fujita, Shoji; Ikeda, Yoshiyuki; Miyata, Masaaki; Shinsato, Takuro; Kubozono, Takuro; Kuwahata, So; Hamada, Narisato; Miyauchi, Takashi; Yamaguchi, Tsuyoshi; Torii, Hiroyuki; Hamasaki, Shuichi; Tei, Chuwa

doi:10.1253/circj.cj-10-0630

Cited by 59 publications

(67 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also reported that Rho kinase plays an important role downstream of PKA during sustained ischemia to confer cardioprotection (167). Other reports support the involvement of SOD induction (48).…”

Section: Factors Underlying the Mechanisms Of Preconditioningsupporting

confidence: 61%

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

Shoji

Komuro

Kitakaze

2011

American Journal of Physiology-Heart and Circulatory Physiology

328

270

View full text Add to dashboard Cite

Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol 301: H1723-H1741, 2011. First published August 19, 2011; doi:10.1152/ajpheart.00553.2011.-Heart diseases due to myocardial ischemia, such as myocardial infarction or ischemic heart failure, are major causes of death in developed countries, and their number is unfortunately still growing. Preliminary exploration into the pathophysiology of ischemia-reperfusion injury, together with the accumulation of clinical evidence, led to the discovery of ischemic preconditioning, which has been the main hypothesis for over three decades for how ischemia-reperfusion injury can be attenuated. The subcellular pathophysiological mechanism of ischemia-reperfusion injury and preconditioninginduced cardioprotection is not well understood, but extensive research into components, including autacoids, ion channels, receptors, subcellular signaling cascades, and mitochondrial modulators, as well as strategies for modulating these components, has made evolutional progress. Owing to the accumulation of both basic and clinical evidence, the idea of ischemic postconditioning with a cardioprotective potential has been discovered and established, making it possible to apply this knowledge in the clinical setting after ischemia-reperfusion insult. Another a great outcome has been the launch of translational studies that apply basic findings for manipulating ischemia-reperfusion injury into practical clinical treatments against ischemic heart diseases. In this review, we discuss the current findings regarding the fundamental pathophysiological mechanisms of ischemiareperfusion injury, the associated protective mechanisms of ischemic pre-and postconditioning, and the potential seeds for molecular, pharmacological, or mechanical treatments against ischemia-reperfusion injury, as well as subsequent adverse outcomes by modulation of subcellular signaling mechanisms (especially mitochondrial function). We also review emerging translational clinical trials and the subsistent clinical comorbidities that need to be overcome to make these trials applicable in clinical medicine. calcium overload; reactive oxygen species; mitochondria; transition pore; comorbidities; clinical trials WHAT DO WE KNOW ABOUT ischemia-reperfusion injury? Because the morbidity and mortality due to ischemic heart diseases have come to the fore in developed countries and are still increasing, it is critically important, both scientifically and socially, to know how cardioprotection is achieved in ischemic myocardium. In fact, in the clinical setting, the application of coronary thrombolysis or immediate percutaneous coronary intervention for faster recanalization has been shown to dramatically improve the outcomes of patients with acute or chronic myocardial ischemia due to impaired coronary blood supply. This finding is founded on the premise that a shorter period of index ischemia...

show abstract

Section: Factors Underlying the Mechanisms Of Preconditioningsupporting

confidence: 61%

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

Shoji

Komuro

Kitakaze

2011

American Journal of Physiology-Heart and Circulatory Physiology

328

270

View full text Add to dashboard Cite

show abstract

“…However, the threshold for activation of TRPV1 may be lowered below a normal body temperature by oxidative stress and the actions of inflammatory modulators (33,34). Waon therapy warms the body evenly at 60°C (12) and reduces oxidative stress (27,28). We therefore anticipated that Waon therapy would reduce the pain associated with CFS.…”

Section: Discussionmentioning

confidence: 99%

Effects of Waon Therapy on Chronic Fatigue Syndrome: A Pilot Study

et al. 2015

Self Cite

View full text Add to dashboard Cite

Objective Chronic fatigue syndrome (CFS) is a disabling condition of unknown etiology, and no definitive therapy has been identified to date. We developed Waon therapy, a form of thermal therapy using a farinfrared dry sauna, and in this study herein examined its feasibility and safety in patients with CFS. Methods Ten consecutive inpatients with CFS stayed in a 60°C sauna for 15 minutes and then rested on a bed under a blanket for an additional 30 minutes outside the sauna room. The treatments were performed once a day, five days a week for four weeks. Perceived fatigue, the primary outcome measure, was evaluated using a numerical rating scale before, during (two weeks after the commencement of therapy) and after therapy. The pain level, evaluated using a numerical rating scale, mood, assessed using the Profile of Mood States questionnaire, and performance status, assessed using a scale developed for CFS patients were also examined before and after therapy. Results Perceived fatigue significantly decreased after therapy, although no significant reductions were observed during therapy. In addition, a negative mood, including anxiety, depression and fatigue, and the performance status significantly improved after therapy. However, the levels of pain and vigor did not change significantly. No patients reported any adverse effects during the therapy. Conclusion These findings suggest that Waon therapy may be a useful and safe treatment for CFS.

show abstract

“…9 Data for Waon therapy have accumulated. It has been shown to reduce preload and afterload through peripheral vasodilation, 9-12 to improve the autonomic nervous system, 13 to reduce oxidative stress, 14 and to improve endothelial function through increases in endothelial nitric oxide (NO) synthase and NO production. 9-15 Cardiac event rate, ventricular arrhythmias, 16 HF symptoms, quality of life, 17 and exercise tolerance 15 can all be improved with Waon therapy.…”

Section: Patient Selectionmentioning

confidence: 99%

Waon Therapy for Managing Chronic Heart Failure　– Results From a Multicenter Prospective Randomized WAON-CHF Study –

Tei

Imamura

Kinugawa

et al. 2016

Circ J

Self Cite

View full text Add to dashboard Cite

Background: Waon therapy improves heart failure (HF) symptoms, but further evidence in patients with advanced HF remains uncertain. Methods and Results:In 19 institutes, we prospectively enrolled hospitalized patients with advanced HF, who had plasma levels of B-type natriuretic peptide (BNP) >500 pg/ml on admission and BNP >300 pg/ml regardless of more than 1 week of medical therapy. Enrolled patients were randomized into Waon therapy or control groups. Waon therapy was performed once daily for 10 days with a far infrared-ray dry sauna maintained at 60°C for 15 min, followed by bed rest for 30 min covered with a blanket. The primary endpoint was the ratio of BNP before and after treatment. In total, 76 Waon therapy and 73 control patients (mean age 66 years, men 61%, mean plasma BNP 777 pg/ml) were studied. The groups differed only in body mass index and the frequency of diabetes. The plasma BNP, NYHA classification, 6-min walk distance (6MWD), and cardiothoracic ratio significantly improved only in the Waon therapy group. Improvements in NYHA classification, 6MWD, and cardiothoracic ratio were significant in the Waon therapy group, although the change in plasma BNP did not reach statistical significance. No serious adverse events were observed in either group. Conclusions:Waon therapy, a holistic soothing warmth therapy, showed clinical advantages in safety and efficacy among patients with advanced HF. (Circ J 2016; 80: 827 -834)

show abstract

Effect of Waon Therapy on Oxidative Stress in Chronic Heart Failure

Cited by 59 publications

References 48 publications

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

Effects of Waon Therapy on Chronic Fatigue Syndrome: A Pilot Study

Waon Therapy for Managing Chronic Heart Failure　– Results From a Multicenter Prospective Randomized WAON-CHF Study –

Contact Info

Product

Resources

About

Effect of Waon Therapy on Oxidative Stress in Chronic Heart Failure

Cited by 59 publications

References 48 publications

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures

Effects of Waon Therapy on Chronic Fatigue Syndrome: A Pilot Study

Waon Therapy for Managing Chronic Heart Failure – Results From a Multicenter Prospective Randomized WAON-CHF Study –

Contact Info

Product

Resources

About

Waon Therapy for Managing Chronic Heart Failure　– Results From a Multicenter Prospective Randomized WAON-CHF Study –